Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4101364 | 0.94 | CHRM3 (0.88) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4104522 | 0.91 | CHRM3 (0.89) | CHRM3CHRM1 | |
| SCHEMBL5530860 | 0.90 | CHRM3 (1.00) | CHRM3CHRM1 | |
| SCHEMBL13649175 | 0.90 | CHRM3 (0.81) | CHRM3CHRM1 | |
| SCHEMBL13649178 | 0.87 | CHRM3 (1.00) | CHRM3CHRM1 | |
| SCHEMBL13649181 | 0.87 | CHRM3 (1.00) | CHRM3CHRM1 | |
| SCHEMBL4098455 | 0.87 | CHRM3 (1.00) | CHRM3CHRM1 | |
| SCHEMBL14435017 | 0.87 | CHRM3 (0.98) | CHRM3CHRM1 | |
| Trifluoroacetic Acid SCHEMBL4111072 | 0.86 | CHRM3 (0.91) | CHRM3CHRM1 | |
| SCHEMBL13649185 | 0.84 | CHRM3 (0.95) | CHRM3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253908-A1 | NOVEL M3 MUSCARINIC ACETYLCHOINE RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRNA3 | CHRM3 1/4885CHRM1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.